Why the FDA Issued Warnings The FDA determined that companies marketing compounded retatrutide: Sold an unapproved new drug without FDA authorization Misbranded products by providing no adequate directions for safe use Improperly claimed compounding exemptions that do not apply to investigational substances In short, these products are not permitted for compounding or distribution under current federal law
[Real Clinical Citations] We include 13 clinical citations
Given the documented effects of GLP-1 and GLP-2 on rodent liver regeneration and their routine therapeutic targeting for other indications, we sought to explore perioperative dynamics of GLP-1 and GLP-2 in patients undergoing hepatic resections
Daneshmand is well-versed in the latest anti-aging solutions and has a team of highly qualified medical aestheticians, RNs, massage therapists, and acupuncturists
The glucagon component is theorized to enhance energy expenditure and lipolysis
"While we traditionally think of therapy choices as having to compete against one another, this is a good example of a complementary relationship between two products that both help optimize the treatment of diabetes." The CEO acknowledged that there is plenty of investor angst over the potential medtech impact from GLP-1 drugs, but he said this angst is probably driven more by people with a bit less "domain knowledge" in medtech and that they seem swayed by headlines touting recently published studies on the new class of medications